SCHEMBL2248286

SCHEMBL2248286

Nc1cnc2ccc(Br)cc2c1Nc1ccccc1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 1/20 0.44
CCNC P24863 1/20 0.44
CDK8 P49336 1/20 0.44
TNF P01375 1/20 0.44
ALDH1A1 P00352 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
HPGD P15428 1/20 0.41
CYP2C19 P33261 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
CD38 P28907 1/20 0.41
ADRB2 P07550 1/20 0.39
PTK2 Q05397 1/20 0.38
FLT1 P17948 1/20 0.38
KDR P35968 1/20 0.38
EGFR P00533 3/20 0.37
MAPK10 P53779 1/20 0.37
RAF1 P04049 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14872845 0.88 TNF (0.46) CSF1RTNFALDH1A1CYP1A2CYP2D6
SCHEMBL2247724 0.87 CCNC (0.59) CSF1RCCNCCDK8SMN1; SMN2CD38
SCHEMBL2248962 0.86 TNF (0.53) CSF1RTNFALDH1A1CYP1A2CYP2D6
SCHEMBL14872860 0.84 PDE4B (0.50) CSF1RTNFALDH1A1CYP1A2CYP2D6
SCHEMBL31439302 0.81 EGFR (0.39) TNFALDH1A1FLT1KDREGFR
SCHEMBL30849407 0.79 ALK (0.43) CSF1RTNFALDH1A1CD38ADRB2
SCHEMBL28805328 0.79 ALK (0.43) CSF1RTNFALDH1A1CD38ADRB2
SCHEMBL12983646 0.77 TNF (0.42) CSF1RTNFEGFRERBB2
SCHEMBL1584898 0.75 TNF (0.45) CCNCCDK8TNFALDH1A1SMN1; SMN2
SCHEMBL31439396 0.74 CSF1R (0.47) CSF1REGFRERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7998972-B2 1H-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases NOVARTIS AG (CH) 2011-08-16 US disclosed
EP-1509521-B1 1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES NOVARTIS AG (CH) 2008-08-20 EP disclosed
US-20050245562-A1 1h-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases NOVARTIS AG (CH) 2005-11-03 US disclosed
EP-1509521-A2 1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES Novartis AG (CH) 2005-03-02 EP disclosed
WO-2003097641-A2 1H-IMIDAZO[4,5-C] QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES NOVARTIS AG (CH) 2003-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245562-A1 1h-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases ABL1, PRKCA, PRKCQ CSF1R 2056/4885CCNC 1514/4885CDK8 464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.